After agreeing to sell certain assets, Spanish firm Grifols won a tentative approval from the US Federal Trade Commission (FTC) under a consent agreement to buy North Carolina biotech Talecris Biotherapeutics for about $4 billion (scripintelligence, 7 June 2010).
Investors embraced the news, driving shares of Talecris up as high as $1.05, or 3.76%, on 2 May, before closing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?